Liver King TRT: What He Said About Medication and PEDs

Who Is Liver King and Why Does This Matter Clinically?

Brian Johnson, operating under the brand name "Liver King," rose to social media prominence between 2021 and 2022 promoting raw organ consumption, extreme cold exposure, and heavy resistance training as the complete explanation for his hypertrophied physique. His following exceeded four million on Instagram at peak growth. The clinical reason this case matters is not celebrity gossip. It is a documented example of how supraphysiologic androgen and growth hormone use is marketed as something else entirely, which influences patient self-prescribing behavior and shapes what patients disclose to their physicians.

Testosterone replacement therapy (TRT) at physiologic doses (typically 100 to 200 mg testosterone cypionate per week in most clinical protocols) produces serum testosterone levels between 400 and 900 ng/dL in most men, restoring a normal range as defined by the American Urological Association (American Urology Association guidelines, 2018). What Johnson's leaked emails described was not TRT. It was a supraphysiologic stack typical of competitive bodybuilding.

The "Ancestral Tenets" Claim

From 2021 onward, Johnson publicly attributed his physique to nine ancestral tenets: sleep, eat, move, shield, connect, cold, sun, fight, and bond. He stated in multiple podcast appearances that these tenets, combined with raw organ meat consumption, were responsible for his muscle mass and body composition. No pharmacological agents were mentioned.

This framing was central to his commercial activity. He sold organ supplements through his company Ancestral Supplements and later his own brand, Liver King. The implicit and sometimes explicit message to consumers was that purchasing and using these products could produce similar results without drugs.

Why Clinicians Should Pay Attention

Research published in the Journal of the Endocrine Society has documented that patients frequently underreport anabolic steroid use to their physicians, often because they perceive stigma or legal risk (Ip et al., 2015, PMID 26279580). High-profile cases where prominent figures deny use and are later exposed may reinforce patient silence. Understanding the specific compounds involved helps clinicians recognize drug-induced laboratory findings that patients may present without context.

The November 2022 Leak: What the Emails Said

On November 18, 2022, fitness YouTuber Derek of More Plates More Dates published leaked email communications purportedly between Brian Johnson and an online fitness coach. The emails contained a detailed description of a performance-enhancing drug protocol.

The Reported Compound List

According to the leaked correspondence, the stack included:

• Testosterone (specific ester not confirmed in public reporting, but context suggests a long-acting ester)
• Human growth hormone (HGH), self-reported at 4 to 5 IU per day
• IGF-1 (insulin-like growth factor 1)
• BPC-157 (a synthetic peptide, not FDA-approved for human use)
• Insulin (reported in some versions of the correspondence)
• Additional unnamed oral anabolics

The reported monthly expenditure on these compounds was approximately $11,000 USD. That figure is clinically significant because it suggests pharmaceutical-grade sourcing rather than dietary supplements.

Pharmacology of the Reported Stack

Human growth hormone at 4 to 5 IU per day is well above any approved therapeutic range. FDA-approved indications for somatropin in adults include adult growth hormone deficiency, with typical replacement doses of 0.1 to 0.3 mg per day (approximately 0.3 to 0.9 IU per day) according to FDA prescribing information for Norditropin (FDA label for Norditropin, NDA 019764). Doses four to five times the upper replacement range are associated with acromegalic side effects including carpal tunnel syndrome, fluid retention, and insulin resistance.

Testosterone at supraphysiologic doses suppresses endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through negative feedback on the hypothalamic-pituitary-gonadal axis. A meta-analysis of 156 studies (N=13,598) in JAMA found that exogenous androgen use is associated with testicular atrophy, infertility, and dyslipidemia at supraphysiologic doses (Bhasin et al., JAMA, 2006, PMID 16609091).

BPC-157 is a 15-amino-acid peptide derived from a protein found in gastric juice. It has no FDA approval for any human indication. Preclinical data in rodent models suggest angiogenic and tendon-healing properties, but no Phase III human trial data exist (Chang et al., 2011, PMID 22110146). Patients who ask about BPC-157 after exposure to influencer content should be counseled that its safety profile in humans is genuinely unknown.

Liver King's Public Confession: What He Actually Said

Two days after the email leak, on November 20, 2022, Brian Johnson published a 10-minute video on his YouTube channel titled "Liver King Comes Clean." Several statements in that video are worth examining against clinical and legal context.

Direct Statements from the Confession Video

Johnson stated on camera: "I lied. I am not natural. I never want to lie again." He confirmed use of anabolic steroids and human growth hormone. He did not provide specific compound names or doses in the video, but he did not dispute the content of the leaked emails.

He framed his use as stemming from body dysmorphia and described a history of steroid use predating the Liver King persona. He stated he had been working with a physician to taper off the compounds, though no physician was named and no documentation was provided publicly.

What He Did Not Confirm

Johnson did not confirm the specific doses cited in the leaked emails. He did not address insulin use. He did not confirm or deny the $11,000 monthly expenditure figure. These omissions are noted here because they affect any clinical interpretation of his exact exposure.

The table below summarizes the evidentiary status of each compound reported in the leak versus what Johnson confirmed publicly.

| Compound | Reported in Leak | Confirmed by Johnson | |---|---|---| | Testosterone | Yes | Yes (general admission) | | HGH (4-5 IU/day) | Yes | Yes (general admission) | | IGF-1 | Yes | Not specifically confirmed | | BPC-157 | Yes | Not specifically confirmed | | Insulin | Yes (some versions) | Not confirmed | | Oral anabolics | Yes | Not specifically confirmed |

The Class-Action Lawsuit: Legal and Commercial Context

In January 2023, a class-action lawsuit was filed against Brian Johnson and his company in federal court, alleging that consumers purchased Liver King-branded supplements based on the false belief that his physique was achievable through the products alone. The complaint cited his public denials of drug use as the basis for deceptive trade practices claims.

This legal action is relevant to a medical content discussion because it documents the commercial mechanism through which misinformation about drug-free physique development reaches consumers. Patients who sought to replicate Johnson's results through supplement purchases may have experienced financial harm. More clinically concerning, some may have subsequently sought black-market anabolic compounds, given the now-documented gap between the marketed result and the actual method.

The FDA has issued multiple warning letters to supplement companies that imply drug-equivalent outcomes, noting that such marketing may violate 21 CFR Part 101 (FDA dietary supplement labeling guidance). The Liver King case illustrates why the FDA's concern about implied drug claims in supplement marketing has real downstream patient-safety implications.

What Supraphysiologic Testosterone Actually Does to the Body

Understanding why Johnson's physique was not achievable through diet and exercise alone requires brief attention to the dose-response relationship between testosterone and muscle mass.

The Bhasin Dose-Response Study

The most cited direct evidence on this question comes from Bhasin et al. (1996, NEJM, N=61), which assigned healthy men to graded testosterone enanthate doses ranging from 25 mg to 600 mg per week while suppressing endogenous testosterone with a GnRH analog. Lean body mass increased in a dose-dependent manner: the 600 mg per week group gained approximately 7.9 kg of fat-free mass over 20 weeks without exercise, compared to 3.2 kg in the 300 mg group and essentially no gain in the 25 mg group (Bhasin et al., NEJM, 1996, PMID 8703167). Men who combined 600 mg per week with strength training gained approximately 6.1 kg more fat-free mass than men who trained without testosterone.

The practical implication: the muscle mass visible on Johnson's frame in 2021 to 2022 was not consistent with the physiologic ceiling achievable through training and nutrition alone. Drug-free competitive natural bodybuilders, competing in organizations with polygraph and urine testing, typically present with very different body composition metrics at similar heights and ages.

HGH and Body Composition

Growth hormone at supraphysiologic doses increases lean mass primarily through water retention and IGF-1-mediated protein synthesis. A Cochrane review of GH supplementation in healthy adults found that while body composition changed (fat mass decreased, lean mass increased), muscle strength did not improve proportionally, and adverse effects including fluid retention, joint pain, and glucose intolerance were common (Liu et al., Cochrane, 2007, PMID 17636837). The cosmetic effect (increased muscle size, reduced body fat) is more pronounced than the functional effect, which explains its popularity in physique sports.

Cardiovascular Risk at High Doses

Supraphysiologic androgen use carries cardiovascular risk that is absent from physiologic TRT when properly monitored. A study published in Circulation (Baggish et al., 2017, N=140) found that long-term anabolic steroid users had significantly impaired left ventricular systolic function and reduced coronary flow reserve compared to age-matched non-users and ex-users (Baggish et al., Circulation, 2017, PMID 28264797). The distinction between medical TRT and the stack Johnson reportedly used is not semantic. It is a clinically meaningful difference in both dose and risk profile.

Differentiating Medical TRT from What Liver King Used

This distinction matters for patients who encounter the Liver King story and ask their clinician about testosterone therapy.

Medical TRT: Defined Parameters

Medical TRT is prescribed for documented hypogonadism, defined by the Endocrine Society as two morning serum testosterone measurements below 300 ng/dL combined with symptoms (Bhasin et al., Endocrine Society Clinical Practice Guideline, 2018, PMID 30265180). FDA-approved formulations include testosterone cypionate injection, testosterone enanthate injection, topical gels (AndroGel, Testim), transdermal patches, and nasal gels (Natesto). Dosing targets serum levels in the mid-normal range (400 to 700 ng/dL), not supraphysiologic levels.

The Spectrum from TRT to Supraphysiologic Use

| Parameter | Medical TRT | Supraphysiologic (reported Liver King stack) | |---|---|---| | Indication | Documented hypogonadism | Physique and performance | | Typical weekly testosterone dose | 100 to 200 mg | Estimated 500 to 1000+ mg | | Target serum testosterone | 400 to 700 ng/dL | Often 1500 to 3000+ ng/dL | | Physician supervision | Required | Typically absent | | Concurrent GH | Not standard | Reported 4 to 5 IU/day | | Cardiovascular monitoring | Hematocrit, lipids, BP | Typically absent | | Legal status | Prescription, Schedule III | Misuse of Schedule III; GH misuse is federal offense |

The Anabolic Steroids Control Act of 1990 and its 2004 amendment classify anabolic steroids as Schedule III controlled substances. Distributing or possessing human growth hormone for any purpose other than an FDA-approved indication is a federal offense under 21 U.S.C. 333(e) (FDA HGH misuse statute reference).

BPC-157 and Peptide Use: What Patients Ask

After the Liver King exposure, web searches for BPC-157 increased substantially. Patients frequently ask whether BPC-157 is legal and whether it can be prescribed.

Regulatory Status

BPC-157 is not approved by the FDA for any human indication. It appeared on the FDA's list of bulk drug substances under evaluation for compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. As of 2023, the FDA has not approved BPC-157 for compounding because it lacks sufficient clinical evidence of safety and efficacy in humans (FDA bulk drug substances list). Physicians cannot legally prescribe it for patient use in the United States under current guidance.

What the Preclinical Data Show

Rodent studies have demonstrated accelerated tendon and ligament healing, gastroprotective effects, and reduced inflammation markers with BPC-157 administration (Seiwerth et al., 1997, PMID 9403886). These findings are interesting and have generated research interest. They do not constitute clinical evidence sufficient to support human prescription use, and patients should be told this directly.

Clinical Takeaways for Practitioners

When patients present having followed Liver King content or similar influencer material, several clinical considerations apply.

History-Taking

Patients may not volunteer anabolic steroid or peptide use. The Endocrine Society recommends asking directly about exogenous androgen use when evaluating low testosterone symptoms, because exogenous androgens will suppress LH and FSH to undetectable levels while total testosterone may read in a normal or elevated range depending on timing of the lab draw relative to injection (Bhasin et al., 2018, PMID 30265180).

Laboratory Findings That Suggest Supraphysiologic Use

• Suppressed LH and FSH with normal or elevated testosterone
• Elevated hematocrit (above 54% is a threshold for TRT dose reduction per Endocrine Society guidelines)
• Elevated IGF-1 above age-adjusted normal range (suggests concurrent GH use)
• Abnormal lipid panel: elevated LDL, reduced HDL
• Elevated liver enzymes with oral anabolic use

Counseling Patients Who Ask About "Ancestral" Protocols

The physique results marketed by Liver King were not achievable through the tenets he publicly promoted. Telling patients this plainly, with the evidentiary basis, is more effective than generalized warnings about steroids. The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% placebo (Wilding et al., NEJM, 2021, PMID 33567185), which is cited here to illustrate a contrasting case: a drug that produces the results it claims in randomized controlled data, with full regulatory disclosure. Patients can be shown what honest pharmaceutical evidence actually looks like.